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Abstract The objective of this study was to assess deep
vein thrombosis and pulmonary embolism (DVT/PE)
recurrence rates and resource utilization among patients
with an initial DVT or PE event across multiple payer
perspectives. Retrospective analyses were performed using
a software tool that analyzes health plan claims to evaluate
treatment patterns and resource utilization for various
cardiovascular conditions. Six databases were analyzed
from three payer perspectives (Commercial, Medicare, and
Medicaid). Patients were C18 years old with a primary
diagnosis of DVT or PE associated with an inpatient and/or
emergency room claim, had received an antithrombotic
within 7 days before or 14 days after index, and had no
diagnosis of atrial fibrillation during follow-up. Outcomes
were assessed over a 1 year period following index. More
PE patients were hospitalized for their index event than
DVT patients (42–59 % DVT and 69–86 % PE) and had
longer mean length of stay (2.35–2.95 days DVT and
3.26–3.76 days PE). Recurrent event rates among PE
patients (12–32 %) were higher than those for DVT
patients (6–16 %) across all payers. The highest rate of
recurrence was observed among the Medicaid population
[23 % overall (VTE); 16 % DVT; 32 % PE]. All-cause
hospitalization in the year following their VTE episode
occurred in 23–67 % DVT patients and 30–68 % PE
patients. Medicaid had the highest proportion of patients
with hospitalizations and ER visits. Recurrent VTE events
and all-cause hospitalizations are relatively common,
especially for patients who had a PE, and among those in
the Medicaid payer population.
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Introduction
Venous thromboembolism (VTE) is a medical condition
referring to all thrombosis (i.e., blood clots) of the veins,
consisting of both deep vein thrombosis (DVT) and pul-
monary embolism (PE). DVT most commonly occurs in
the deep veins of the leg, although it can also occur in veins
of the upper extremities, the pelvis, abdomen, and cerebral
venous sinuses. PE, a more severe manifestation of VTE,
includes either the formation of a thrombosis in blood
vessels or the embolization of thrombi from other areas of
the body into pulmonary circulation. It is estimated that the
annual incidence of DVT/PE is approximately 1–2 persons
per 1,000 with the risk increasing significantly with age,
presence of cancer, recent surgery, or prior DVT or PE
events [1–3].
With more than half of DVT/PE cases being hospital-
acquired [4], DVT/PE is associated with substantial
healthcare resource utilization and costs. A retrospective
analysis of administrative claims data from 2004–2008
estimated that patients with a DVT or PE event had
approximately $16,000 higher mean annual all-cause
medical costs compared to matched patients without DVT
or PE ($33,000 vs. $17,000), with hospitalizations repre-
senting the primary driver of the difference in cost
($17,174 vs. $6,515) [5].
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The recurrence rate for DVT/PE is relatively high,
estimated at between 5 and 10 % within the first year after
an initial DVT or PE event, with recurrence rates up to
30 % within 8 years [6–8]. A study by Bullano et al. found
that 12.1 and 18.5 % of DVT and PE patients experienced
a recurrent VTE hospitalization over a 21-months follow-
up period, respectively. Patients with a recurrent event
experienced an average of 1.26 hospitalizations during
follow-up, with each hospitalization averaging $12,326 per
event [9]. An analysis of hospital administrative claims
data by Spyropolous [10] found that within 1 year of an
initial DVT or PE event, 5.3 and 14.3 % of patients
experienced a hospitalization with a primary or secondary
diagnosis of DVT/PE, respectively, with the mean cost of
readmission being higher than the index event.
DVT/PE events and associated readmissions represent a
particular challenge to the provision of quality care for U.S.
hospitals and healthcare providers, with many health policy
organizations implementing quality metrics aimed at
reducing the incidence of preventable rehospitalizations,
including organizations such as the Joint Commission,
National Quality Forum, and Centers for Medicare and
Medicaid Services [11, 12]. Given the relatively high like-
lihood of recurrence among DVT/PE patients, and the recent
focus on quality measures in the evaluation of healthcare,
robust data on the healthcare resource use associated with
DVT/PE and DVT/PE recurrence could prove useful to
various health plans charged with evaluating quality metrics.
Recent published data on the risk of recurrent DVT or
PE and associated resource use across multiple payer per-
spectives are limited. A 2012 publication by Lefebvre [5]
used data from 2008 or earlier on commercial, Medicare,
and Medicaid beneficiaries to assess the healthcare costs
and risk of recurrence for patients diagnosed with DVT or
PE; however, results were not stratified by payer type.
Another 2012 study of VTE recurrence and healthcare
utilization evaluated differences between Medicaid and
commercially insured patients, but only included patients
aged less than 18 years [13]. Given this data gap, the
objective of this study was to assess DVT/PE recurrence
rates and resource utilization, including all-cause 30 days
readmissions rates, all-cause hospitalizations and all-cause
ER visits, among patients with an initial DVT or PE event
across multiple payer perspectives.
Methods
Overview
This retrospective database analysis used 2 years of
administrative claims records from six different databases
and three different payer perspectives: Commercial
perspective—IMS LifeLink Database (IMS), Clinformat-
icsTM DataMart, a product of OptumInsight Life Sciences,
Inc. (Eden Praire, MN) (Optum), Truven MarketScan
Commercial Database (MSCommercial); Medicare per-
spective—Truven MarketScan Medicare Supplemental
Database (MSMedicare), the Humana Medicare database
(Humana); Medicaid perspective—Medicaid database for a
southern US state (Medicaid). Given the large sample sizes
in the IMS, Optum, MSCommercial, MSMedicare, and
Humana databases, a 10 % random sample was selected
from each of these, while the full Medicaid sample was
used.
Patients included in the analysis had a primary diagnosis
of either DVT or PE associated with an inpatient and/or
emergency room claim (index date), had received an
antithrombotic agent within 7 days before or 14 days after
index, and had no diagnosis of atrial fibrillation during a
1 year period after index (follow-up). Study measures
included demographics (e.g., age and sex), index hospi-
talization length of stay (LOS), recurrent DVT/PE-related
hospitalizations, all-cause 30 days readmission rates, and
the frequency of all-cause hospitalizations and ER visits
during follow-up.
A condition-specific software tool that analyzes health
plan claims to evaluate treatment patterns and resource
utilization for various cardiovascular conditions was used
for this analysis [Anticoagulant quality improvement ana-
lyzer (AQuIA)]. The tool provides a common analysis
platform, which ensures that various population health data
are evaluated in a consistent way. All logic utilized by the
tool for patient selection and measure creation are similar
to that of traditional retrospective database analyses, and
are documented in the patient selection and study measures
sections of this paper. The goal of utilizing this tool was to
eliminate variations in outcome definitions and methodol-
ogy, and focus on understanding how findings vary across
populations that differ based on age, comorbidities, and
other factors.
Data sources
This study used six different de-identified, integrated dat-
abases including medical and pharmacy claims. Diagnoses
and procedures were identified based on International
classification of diseases ninth revision clinical modifica-
tion (ICD-9-CM) and current procedural terminology
(CPT) codes from patients’ medical claims, while medi-
cation use was assessed based on national drug codes
(NDC) from patients’ pharmacy claims.
The IMS LifeLink Health Plan Claims Database is a
commercial database consisting of approximately 55 mil-
lion patients from over 75 managed care organizations
across the US and several million Medicare managed-care
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enrollees from four US geographical regions. The Clin-
formaticsTM DataMart database, a product of OptumInsight
Life Sciences, Inc. (Eden Prairie, MN), consists of a single,
large insurance healthcare plan that includes more than 53
million unique members spanning over 12 years. The
Truven MarketScan Commercial Claims and Encounter
Database is constructed from privately insured paid medi-
cal and prescription drug claims for approximately 30
million employees and their dependents (in 2010) [14]. The
MarketScan Medicare Supplemental Database contains the
healthcare experience of individuals with Medicare sup-
plemental insurance paid by employers for approximately
3.42 million retirees (in 2010) [14]. The Humana database
consists of the entire fully-insured commercial and Medi-
care members belonging to the Humana health plan. The
database includes 3.4 million Medicare members, includ-
ing 1.4 million Medicare advantage prescription drug
members; only data from Medicare members of the Hu-
mana health plan were used in this analysis. The Medicaid
program database from a southeastern US state used in this
analysis covers low-income or disabled individuals and
consists of two files: a claims file, with details on medical
and pharmacy utilization; as well as an eligibility file, with
details on monthly enrollment and patient demographics.
Two-years of claims available from each database were
used in this study; IMS, 07/2010–06/2012; Optum,
04/2010–03/2012; MSCommercial, 07/2009–06/2011;
MSMedicare, 07/2009–06/2011; Humana, 07/2010–6/
2012; and Medicaid, 07/2008–06/2010.
Patient selection
Patients were included in the study if they were C18 years
of age, had at least one primary diagnosis of VTE (i.e.,
DVT or PE) associated with an inpatient and/or emergency
room visit, had received an antithrombotic agent within
7 days before or 14 days after index, and did not have a
diagnosis for atrial fibrillation (ICD-9-CM code 427.31)
during the follow-up period (i.e., 1 year post index). The
index date was defined as the date of the first DVT/PE
diagnosis observed in the available data, identified by the
following ICD-9-CM codes (DVT–451.1x, 451.2x, 453.0x,
453.2, 453.3x, 453.40, 453.41, 453.42, 453.8x, 997.2x; PE–
415.1x). Patients were classified into mutually exclusive
cohorts (i.e., DVT or PE) based on the diagnosis code
associated with the index claim. Receipt of antithrombotic
agents were identified by NDC codes.
Patients were followed over a period of 1 year after the
index date (i.e., the follow-up period). All study measures
were evaluated during the follow-up period. Additional cri-
teria for continuous eligibility were not applied; however,
patients who were Medicare and/or health maintenance
organization eligible anytime during the 2-years period were
excluded in the Medicaid database, in order to ensure the
availability of all claims within this database.
Study measures
Demographics (i.e., age and sex) and comorbidities at
time of index were evaluated for all patients meeting
inclusion criteria. The LOS of the index DVT/PE hos-
pitalization was calculated among patients experiencing
an inpatient hospitalization as their first DVT/PE claim.
LOS was calculated as the difference between the dis-
charge and admission dates recorded on the index inpa-
tient stay.
The percentage of patients experiencing a recurrent
DVT/PE-related hospitalization during the follow-up per-
iod was also evaluated. Patients with a primary DVT/PE
coded inpatient visit (determined by the same ICD-9-CM
codes used for index event identification) at any point after
the initial index event were flagged as experiencing a
recurrent hospitalization. The percentage of patients with
any (i.e., not disease-specific) inpatient hospitalization,
inpatient hospitalization within 30 days of index, and ER
visit were reported for the follow-up period, as well as the
mean number of visits per patient (among those experi-
encing an event) for each resource category. All-cause
inpatient hospitalizations and ER visits were identified
based on inpatient hospital/ER visit CPT or UB-92 revenue
codes.
Data analyses
All analyses were descriptive in nature. Categorical vari-
ables were summarized using counts and sample propor-
tions. Mean values were reported for continuous measures.
Study measures were reported for the overall study cohort
(i.e., overall VTE), as well as stratified by index event
diagnosis (i.e., DVT or PE).
SAS software (Version 9.3, SAS Institute, Cary, NC)
was used for extracting medical/pharmacy claims and
demographic information from all databases, and for
organizing the data in the proper format to be utilized by
the AQuIA software tool, which carried out the analyses
that produced the study outcomes. The software tool is
condition-specific and enables uploading pharmacy and
medical claims data via a simple point-and-click method to
produce results for a series of predetermined measures and
generate sample-specific reports. The programming logic
behind all predetermined measures has been outlined in the
sections above. All personal identifiers were removed
before data were uploaded to the tool.
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Result
Demographic and clinical characteristics
The number of patients meeting the cohort selection cri-
teria varied across databases; 1,055 IMS (327 DVT; 728
PE), 505 Optum (160 DVT; 345 PE), 1,541 MSCommer-
cial (548 DVT; 993 PE), 510 MSMedicare (198 DVT; 312
PE), 697 Humana (198 DVT; 499 PE), and 249 Medicaid
(146 DVT; 103 PE). Average age varied between
47–77 years for patients with DVT, and between
46–75 years among patients diagnosed with PE, with
Medicaid typically having a younger population, and the
Medicare databases (MSMedicare and Humana) having an
older cohort. On average, more than half of study patients
were female (Table 1).
Averaging across all databases, more than 50 % of
patients meeting inclusion criteria had hypertension
(41–80 % DVT; 43–83 % PE), and over 40 % had cancer
(32–53 % DVT; 33–50 % PE). Diabetes (11–40 % DVT;
18–36 % PE) and hyperlipidemia (30–60 % DVT;
30–63 % PE) were other commonly observed comorbid
conditions.
Index hospitalization and recurrent VTE-related
hospitalizations
The majority of patients identified with an index PE event
were associated with an inpatient hospitalization (69–86 %
across all databases) as opposed to during an ER visit only
(14–31 %), while patients identified with an index DVT
event had an equal likelihood of receiving an index diag-
nosis in either place of service (48 % index event in
inpatient hospitalization across commercial plans (weigh-
ted average); 57 % across Medicare databases; 42 %
Medicaid). Patients with an index hospitalization for PE
Table 1 Patient demographics and clinical characteristics
Characteristics IMS Optum MSCommercial MSMedicare Humana Medicaid
DVT PE DVT PE DVT PE DVT PE DVT PE DVT PE
Number of patients 327 728 160 345 548 993 198 312 198 499 146 103
Mean age 57.84 55.78 50.14 50.93 49.11 48.74 77.07 74.8 74.42 73.12 47.36 46.14
Female (%) 63 60 53 49 57 50 58 53 59 55 58 71
Age Groups
18–29(%) 3 4 8 5 6 7 0 0 0 0 13 14
30–39(%) 13 6 12 14 13 13 0 0 0 0 15 17
40–49(%) 9 26 28 25 26 26 0 0 0 0 25 26
50–59(%) 19 22 23 30 36 33 0 0 0 0 27 29
60–64(%) 22 18 21 12 19 18 1 1 5 5 16 11
65? 34 24 9 14 1 2 99 99 65 65 5 3
Comorbidities (%)
COPD 3 6 3 5 3 4 10 13 14 19 13 27
Hypertension 59 60 43 48 41 43 66 61 80 83 73 72
Cancer 53 44 32 38 34 33 45 46 47 50 28 44
Diabetes 25 24 11 18 16 18 29 26 38 36 40 36
Heart failure 9 10 6 7 6 7 11 20 24 23 25 20
Previous AMI 0 1 1 2 1 2 3 3 6 8 4 2
Coronary artery disease 9 12 12 8 9 9 26 27 26 36 18 25
Hyperlipidemia 34 41 34 40 30 30 38 37 60 63 43 40
Chronic kidney disease 16 9 9 7 6 6 19 13 32 24 21 12
Valvular disease 0 26 10 20 9 14 14 16 21 21 18 30
Diabetic neuropathy 0 1 3 1 1 2 6 2 8 7 10 8
Peripheral vascular disease 3 7 9 5 9 4 20 14 26 19 21 12
Retinopathy 0 0 0 1 0 1 3 1 5 2 4 2
Data source IMS, 07/2010–06/2012; Optum, 04/2010–03/2012; MSCommercial, 07/2009–06/2011; MSMedicare, 07/2009–06/2011; Humana,
07/2010–06/2012; Medicaid, 07/2008–06/2010
DVT deep vein thrombosis, PE pulmonary embolism, COPD chronic obstructive pulmonary disease, AMI acute myocardial infarction
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had longer lengths of stay for the index event than those
with DVT (2.35–2.95 days for DVT vs. 3.26–3.76 days for
PE), with relatively consistent findings across all databases
(Table 2).
During the one year follow-up period, recurrent
VTE-related hospitalizations (i.e., primary DVT/PE
coded inpatient visit after initial index event) occurred
in 10 to 23 % of patients across the databases. The
highest rates of recurrent VTE-related hospitalizations
occurred in the Medicare (19–21 %) and Medicaid
(23 %) populations. Approximately 16 % of patients
with DVT and 32 % of patients with PE experienced a
recurrent VTE-related hospitalization during follow-up
in the Medicaid database. In the Medicare databases, 13
and 14 % of DVT and 23 and 24 % of PE patients
experienced a recurrent hospitalization in the MSMed-
icare and Humana populations, respectively. Recurrent
event rates among PE patients (12–32 %) were higher
than those for DVT patients (6–16 %) across all dat-
abases (Fig 1).
All-cause resource utilization
All-cause hospitalization in the year following the index
event was common across payers, with the highest rate
among Medicaid patients (67 % overall VTE), and a range
of 27–49 % across other databases (Table 3). Rates of
hospitalization among PE patients were greater than or
equal to those among DVT patients in each study database
(range 23–67 % DVT; 30–68 % PE). The mean number of
hospitalizations during follow-up among those experienc-
ing a hospitalization was relatively consistent for the DVT
(range 1.69–2.34) and PE (range 1.61–2.18) populations
across commercial and Medicare databases, and was higher
in the Medicaid database (4.68 DVT; 4.7 PE).
All-cause hospitalizations within 30 days of the index
event occurred in 12–30 % of DVT patients and 14–36 %
of PE patients across all databases. All-cause ER visits
were also common throughout the study period, occurring
in 27–72 % of DVT patients and 29–75 % of PE patients.
As with hospitalizations, Medicaid patients had the highest
Table 2 Average length of stay among patients with DVT or PE index hospitalization
Measure IMS Optum MSCommercial MSMedicare Humana Medicaid
DVT PE DVT PE DVT PE DVT PE DVT PE DVT PE
Number of patients 327 728 160 345 548 993 198 312 198 499 146 103
Has index hospitalization
N 163 621 74 266 261 763 117 241 107 427 61 71
% 50 85 46 77 48 77 59 77 54 86 42 69
Mean length of stay 2.35 3.26 2.65 3.76 2.59 3.46 2.91 3.57 2.84 3.29 2.95 3.64
Data source IMS, 07/2010-06/2012; Optum, 04/2010–03/2012; MSCommercial, 07/2009–06/2011; MSMedicare, 07/2009–06/2011; Humana,
07/2010–06/2012; Medicaid, 07/2008–06/2010
































Fig. 1 Presence of recurrent
VTE hospitalization up to
1 year following index,
stratified by VTE type and
database. VTE venous
thromboembolism, DVT deep
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Our study used a common analysis platform to assess VTE
recurrence rates, all-cause 30 day readmission rates, and
all-cause hospitalizations and ER admissions among
patients with a diagnosis of DVT or PE using data from
commercial, Medicare, and Medicaid payer perspectives.
The overall rate of recurrent VTE-related hospitalization
was relatively common (i.e., 6–16 % DVT; 12–32 % PE)
over the 1-year follow-up period. Rates were typically
higher among patients with an index PE event than DVT
event, and the highest rates occurred among Medicaid
patients. 30-days hospital readmission rates shared a sim-
ilar likelihood of occurrence, with rates being the highest
among patients in the Medicare and Medicaid databases.
All-cause hospitalizations and ER visits in the year fol-
lowing index DVT/PE episode were common across all
study databases, with approximately one-third of patients
experiencing either event during the follow-up period.
Comparison with other literature
In our analysis, inclusion criteria identified approximately
twice as many PE patients as DVT (3,057 vs. 1,590) across
all included study databases. In order to ensure that
included patients experienced an index event, DVT or PE
diagnosis was required to be identified through an inpatient
or ER visit. Given that approximately 50 % of DVT
patients are treated initially in the outpatient setting [15],
this strict inclusion criterion resulted in a VTE population
with a different composition than that found in clinical
practice, where approximately two-thirds of VTE patients
typically have a DVT diagnosis [16].
Although there are few studies that have evaluated these
outcomes across multiple payers, our findings are broadly
consistent with previously published estimates of VTE recur-
rence, all-cause and 30 days hospitalization rates, and index
event length of stay in a general VTE patient population. A
2005 study conducted by Bullano and colleagues found a rate
of recurrence of 13.4 % (12.1 % DVT; 18.5 % PE) over a
period of 21 months among commercially insured patients
with no prior history of VTE using a more narrow set of VTE
diagnosis codes than the present study [9]. This estimate is
comparable to the results identified among commercially
insured patients in our study over 12 months (e.g., 15 %
overall recurrence rate in MSCommercial; 11 % DVT, 17 %
PE). Furthermore, Detalziweig 2010, using the Integrated
Healthcare Information services database, reported an 11 %
recurrent VTE hospitalization rate over a variable follow-up
period [17]. Spyropolous et al. [10] evaluated the direct med-
ical costs of subsequent hospital readmissions among patients
with VTE from 30 managed care organizations. During a
1 year follow-up period, 19.6 % of patients were rehospital-
ized with a primary or secondary diagnosis of DVT or PE.
A recent publication by Khorana and colleagues found
that commercially insured patients with cancer and VTE
experienced an average of 1.38 all-cause hospitalizations
during the 12 months after index VTE event [18]. While
the patients included in our study were not required to have
a diagnosis of cancer, 34–53 % had cancer as a baseline
comorbidity, resulting in a similar range among included
commercial databases (1.63–1.88). Results for index VTE
length of stay and 30 day readmission also are comparable
to recently published studies. A 2011 electronic medical
record and chart review among patients with a diagnosis of
VTE found that insured patients had an average index
length of stay of 3.7 days, with approximately 9 % expe-
riencing a hospital readmission within 30 days and 11 %
being readmitted to the ER within 30 days [19].
Implications of our work
The high rate of recurrent VTE-related hospitalizations
(10–23 %) and 30 days all-cause hospitalizations (13–32 %)
observed in our study represent significant economic issues
for both healthcare providers and payers. In addition to the
high direct costs associated with recurrent VTE-related hos-
pitalizations (estimated at over $10,000 for DVT and $16,000
for PE) [10], a high rate of rehospitalization has a negative
impact on quality of care, which has become an increasingly
important metric in the evaluation of healthcare during recent
years. In 2008 the Joint Commission, in collaboration with the
National Quality Forum, established a VTE prevention and
quality measurement initiative. The initiative established six
VTE quality measures which aim to reduce the incidence of
preventable hospital-acquired DVT and PE, as well as the
incidence of VTE readmissions [11]. Quality metrics include
items such as adequate venous thromboembolism prophylaxis
and accurate anticoagulation instructions at discharge. While
not currently tied to reimbursement, these quality measures
are collected and published annually by the Joint Commission.
The Affordable Care Act has also established Medicare
reimbursement penalties for hospitals with excessive re-
admission rates within 30 days of hospital discharge. Penal-
ties currently only apply to acute myocardial infarction, heart
failure, and pneumonia readmissions; however, additional
conditions are expected to be added to the program in
upcoming years [12].
Our findings suggest a possible need for both public and
private payers to monitor readmission rates among this
440 K. Lang et al.
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patient population. A reduction in readmissions could
potentially lessen the direct costs associated with VTE for
the managed care organization while improving the quality
of care provided to the patient. This is particularly
important among the Medicaid population, where rates of
VTE recurrence over the one year follow-up period were
the highest among all analyzed populations (23 % overall
VTE population; 16 % DVT; 32 % PE). Given that data on
Medicaid-specific VTE recurrence rates are limited in the
published scientific literature, our study provides rationale
for further investigation among this VTE subpopulation.
Additional analyses that aim to determine the sociodemo-
graphic and clinical characteristics associated with VTE
recurrence among Medicaid patients would help to further
understand the results observed in our analysis, and provide
useful data for identifying patients at high risk of
recurrence.
Limitations
This study was designed as a descriptive analysis and was
not intended to compare outcomes across different cohorts
(e.g., techniques such as propensity score matching were
not employed). The software tool did not allow analyses of
dispersion around the mean values (e.g., using standard
deviation or ranges), and continuous patient enrollment
during follow-up was not required by the tool, potentially
resulting in the underestimation of events and resource use.
Furthermore, the primary objective of this study was to
analyze the proportion of patients experiencing recurrent
VTE events during a 1 year period from multiple payer
perspectives. Additional analyses that evaluate the time to
recurrent events, predictors of recurrent events/30 days
hospitalizations, or the correlation between recurrent
events and treatment status among this patient population
would provide further insight into the outcomes observed
in this study and are warranted.
Due to strict inclusion criteria which identified DVT or
PE events based on inpatient or ER claims, patients with
initial DVT treatment in an outpatient setting were not
included in this study, potentially decreasing the eligible
sample size for analysis. Study findings and their impli-
cations are therefore limited to DVT and PE patients ini-
tially treated in the inpatient/ER setting.
These analyses relied on claims data, which are used
primarily for administrative (i.e., billing and operations)
purposes and therefore do not reflect all clinical variables
that are taken into account by physicians when making
treatment decisions. It is also challenging to ensure that
subsequent admissions for VTE are new events, as opposed
to re-hospitalizations for the index event, when using the
limited clinical data available in administrative claims. To
address this limitation of the data source, we required that
all recurrent VTE events have a primary admitting diag-
nosis of DVT or PE in an inpatient hospitalization setting.
These criteria help to limit the identification of events in
which a prior DVT/PE diagnosis is coded during a non-
VTE related hospitalization. Furthermore, while the
Medicare and commercial databases had broad geograph-
ical representation, the Medicaid population analyzed in
this study only reflects data collected for a single US state.
Conclusion
Findings from this analysis demonstrate the high rate of
resource utilization and relatively common occurrence of
subsequent VTE hospitalizations among patients with an
initial VTE event. Results were similar across multiple
payer perspectives, a potential observation of interest to
clinicians and policymakers charged with improving
quality of care among a diverse patient population.
Increased use of the analyzer utilized in this analysis and
similar software may support enhanced education efforts
aimed at improving these outcomes.
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